ANI Pharmaceuticals, Inc. – NASDAQ:ANIP
ANI Pharmaceuticals stock price today
$89.9
+35.48
+65.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
ANI Pharmaceuticals stock price monthly change
-14.31%
month
ANI Pharmaceuticals stock price quarterly change
-14.31%
quarter
ANI Pharmaceuticals stock price yearly change
-1.29%
year
ANI Pharmaceuticals key metrics
Market Cap | 1.11B |
Enterprise value | 868.92M |
P/E | -12.75 |
EV/Sales | 2.74 |
EV/EBITDA | 36.27 |
Price/Sales | 1.99 |
Price/Book | 1.86 |
PEG ratio | -1.23 |
EPS | 1.70 |
Revenue | 517.46M |
EBITDA | 112.28M |
Income | 35.54M |
Revenue Q/Q | 28.69% |
Revenue Y/Y | 44.26% |
Profit margin | -15.14% |
Oper. margin | -8.13% |
Gross margin | 56.13% |
EBIT margin | -8.13% |
EBITDA margin | 21.7% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeANI Pharmaceuticals stock price history
ANI Pharmaceuticals stock forecast
ANI Pharmaceuticals financial statements
| Jun 2023 | 116.54M | 6.24M | 5.36% |
|---|---|---|---|
| Sep 2023 | 131.82M | 9.94M | 7.54% |
| Dec 2023 | 131.65M | 1.15M | 0.88% |
| Mar 2024 | 137.43M | 18.20M | 13.25% |
| Mar 2024 | 137.43M | 18.20M | 13.25% |
|---|---|---|---|
| Sep 2025 | 140.46M | 21.33M | 15.19% |
| Oct 2025 | 144.45M | 26.80M | 18.55% |
| Dec 2025 | 149.21M | 27.96M | 18.74% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | 0.03% |
| 2022 | 0.25% |
| 2023 | 0.16% |
| Jun 2023 | 859341000 | 424.86M | 49.44% |
|---|---|---|---|
| Sep 2023 | 889914000 | 435.20M | 48.9% |
| Dec 2023 | 904422000 | 471.67M | 52.15% |
| Mar 2024 | 914524000 | 462.56M | 50.58% |
| Jun 2023 | 20.62M | -6.82M | 80.15M |
|---|---|---|---|
| Sep 2023 | 32.16M | -4.55M | 3.75M |
| Dec 2023 | 44.74M | -4.77M | -11.91M |
| Mar 2024 | 18.26M | 8.93M | -19.72M |
ANI Pharmaceuticals alternative data
| Aug 2023 | 600 |
|---|---|
| Sep 2023 | 600 |
| Oct 2023 | 600 |
| Nov 2023 | 600 |
| Dec 2023 | 600 |
| Jan 2024 | 600 |
| Feb 2024 | 600 |
| Mar 2024 | 642 |
| Apr 2024 | 642 |
| May 2024 | 642 |
| Jun 2024 | 642 |
| Jul 2024 | 642 |
ANI Pharmaceuticals other data
45.28%
-17.59%
of ANIP is owned by hedge funds
96
-27
7.36M
-2.88M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 50250 |
| Feb 2024 | 0 | 250 |
| Mar 2024 | 0 | 159632 |
| Apr 2024 | 0 | 70250 |
| May 2024 | 0 | 90919 |
| Jun 2024 | 0 | 78235 |
| Jul 2024 | 0 | 70250 |
| Aug 2024 | 0 | 250 |
| Sep 2024 | 0 | 250 |
| Oct 2024 | 0 | 250 |
| Nov 2024 | 0 | 40231 |
| Dec 2024 | 0 | 1000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | DAVIS KRISTA officer: SVP, CHIEF HR OFFICER | Common Stock | 1,000 | $60 | $60,000 | ||
Option | LALWANI NIKHIL director, officer.. | Common Stock | 30,000 | $29 | $870,000 | ||
Sale | LALWANI NIKHIL director, officer.. | Common Stock | 30,000 | $57.95 | $1,738,500 | ||
Sale | LALWANI NIKHIL director, officer.. | Common Stock | 3,481 | $58.3 | $202,942 | ||
Option | LALWANI NIKHIL director, officer.. | Stock Option (right to buy) | 30,000 | $29 | $870,000 | ||
Sale | MUTZ CHRISTOPHER officer: HEAD OF RARE DISEASE | Common Stock | 6,500 | $57.7 | $375,050 | ||
Sale | COOK MEREDITH officer: SR. VP, GENERAL COUNSE.. | Common Stock | 250 | $61.36 | $15,340 | ||
Sale | COOK MEREDITH officer: SR. VP, GENERAL COUNSE.. | Common Stock | 250 | $57.19 | $14,298 | ||
Sale | COOK MEREDITH officer: SR. VP, GENERAL COUNSE.. | Common Stock | 250 | $56.82 | $14,205 | ||
Sale | COOK MEREDITH officer: SR. VP, GENERAL COUNSE.. | Common Stock | 250 | $59.62 | $14,905 |
| Quarter | Transcript |
|---|---|
| Q1 2024 10 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
ANI Pharmaceuticals: A Short-Term Buying Opportunity
ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
3 Catalysts Could Drive ANI Pharmaceuticals' PPS Growth Through November 2023
ANI Pharmaceuticals Is Undervalued When Considering Their Unadvertised Pipeline
2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit
Insider Weekends: Return Of The Meme Stocks - GameStop And AMC Entertainment
ANI Pharmaceuticals: Back In The Buy Zone
A Low Valuation, High Growth Target: ANI Pharmaceuticals
Post Earnings Assessment On ANI Pharmaceuticals
-
What's the price of ANI Pharmaceuticals stock today?
One share of ANI Pharmaceuticals stock can currently be purchased for approximately $89.9.
-
When is ANI Pharmaceuticals's next earnings date?
Unfortunately, ANI Pharmaceuticals's (ANIP) next earnings date is currently unknown.
-
Does ANI Pharmaceuticals pay dividends?
No, ANI Pharmaceuticals does not pay dividends.
-
How much money does ANI Pharmaceuticals make?
ANI Pharmaceuticals has a market capitalization of 1.11B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 53.87% to 486.82M US dollars.
-
What is ANI Pharmaceuticals's stock symbol?
ANI Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ANIP".
-
What is ANI Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of ANI Pharmaceuticals?
Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ANI Pharmaceuticals's key executives?
ANI Pharmaceuticals's management team includes the following people:
- Mr. Stephen P. Carey Senior Vice President of Fin. & Chief Financial Officer(age: 54, pay: $877,180)
- Mr. Nikhil Lalwani Pres, Chief Executive Officer & Director(age: 47, pay: $844,150)
- Mr. James G. Marken Senior Vice President of Operations & Product Devel.(age: 62, pay: $715,620)
-
How many employees does ANI Pharmaceuticals have?
As Jul 2024, ANI Pharmaceuticals employs 642 workers.
-
When ANI Pharmaceuticals went public?
ANI Pharmaceuticals, Inc. is publicly traded company for more then 25 years since IPO on 5 May 2000.
-
What is ANI Pharmaceuticals's official website?
The official website for ANI Pharmaceuticals is anipharmaceuticals.com.
-
Where are ANI Pharmaceuticals's headquarters?
ANI Pharmaceuticals is headquartered at 210 Main Street West, Baudette, MN.
-
How can i contact ANI Pharmaceuticals?
ANI Pharmaceuticals's mailing address is 210 Main Street West, Baudette, MN and company can be reached via phone at +218 6343500.
ANI Pharmaceuticals company profile:
ANI Pharmaceuticals, Inc.
anipharmaceuticals.comExchange:
NASDAQ
Full time employees:
642
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
210 Main Street West
Baudette, MN 56623
Baudette, MN 56623
CIK: 0001023024
ISIN: US00182C1036
CUSIP: 00182C103
